JPMorgan Chase & Co. Buys 326,348 Shares of IDEXX Laboratories, Inc. $IDXX

JPMorgan Chase & Co. increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 60.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 869,930 shares of the company’s stock after purchasing an additional 326,348 shares during the period. JPMorgan Chase & Co. owned approximately 1.09% of IDEXX Laboratories worth $555,802,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. STF Management LP increased its holdings in IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after buying an additional 16 shares during the period. Clearstead Trust LLC increased its stake in IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after acquiring an additional 16 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in IDEXX Laboratories by 4.4% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after acquiring an additional 16 shares during the last quarter. Moss Adams Wealth Advisors LLC raised its position in IDEXX Laboratories by 3.3% during the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after purchasing an additional 17 shares in the last quarter. Finally, Stratos Wealth Partners LTD. lifted its stake in IDEXX Laboratories by 1.7% during the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after purchasing an additional 18 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IDXX. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. UBS Group decreased their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Stock Up 1.4%

Shares of NASDAQ IDXX opened at $634.90 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The firm has a market cap of $50.70 billion, a PE ratio of 48.58, a price-to-earnings-growth ratio of 3.81 and a beta of 1.67. The company has a 50 day simple moving average of $680.64 and a 200 day simple moving average of $669.42.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the business posted $2.53 EPS. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.